Catalyst Event
ABL Bio Inc (298380) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/28/2026, 12:00:00 AM
Partner Compass Therapeutics announced on April 27 that the Phase 2/3 trial for biliary tract cancer drug Tovecimig (ABL001) met its Progression-Free Survival (PFS) endpoint but failed to meet the key Overall Survival (OS) endpoint. The news led to a stock price decline of over 20%.
Korean Translation
파트너사 컴퍼스 테라퓨틱스가 4월 27일 발표한 담도암 치료제 토베시미그(ABL001)의 임상 2/3상 결과, 무진행생존기간(PFS) 목표는 충족했으나 주요 지표인 전체생존기간(OS)은 충족하지 못함. 이 소식으로 주가가 20% 이상 급락함.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM